arrow
G

Glenn J. Jaffe

Duke University Medical Center
H指数:82
被引数:3.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Danicopan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results From the Phase 2 Randomized OnwarD Trial

达尼考潘治疗与年龄相关性黄斑变性相关的地图样萎缩:来自OnwarD二期随机试验的结果

2026-08-170
OAAI
GOLDEN: Efficacy and Safety of Complement Factor B Antisense, Sefaxersen, in Geographic Atrophy due to Age-Related Macular Degeneration

GOLDEN:补体因子B反义药物Sefaxersen在年龄相关性黄斑变性引起的地理性萎缩中的疗效与安全性

2026-07-280
OAAI
Low Rates of Fibrosis in Eyes Treated with the Port Delivery Platform with Ranibizumab or with Monthly Ranibizumab in the Archway Trial

在Archway试验中,使用Port Delivery平台或每月注射雷珠单抗治疗的眼睛中纤维化发生率较低

2026-06-080
OAAI
LONG-TERM EFFICACY AND SAFETY OF PHOTOBIOMODULATION IN DRY AGE-RELATED MACULAR DEGENERATION (LIGHTSITE III: 24-MONTH ANALYSIS)

光生物调节在干性年龄相关性黄斑变性中的长期疗效与安全性(LIGHTSITE III:24个月分析)

2026-05-013
PRE
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trial

阿瓦辛卡帕德·贝戈尔(Avacincaptad pegol)用于年龄相关性黄斑变性继发的地理性萎缩:GATHER2三期试验2年的疗效和安全性结果

2025-12-150
OAAI
Corrigendum to “Baseline Visual Field Findings in the RUSH2A Study: Associated Factors and Correlation With Other Measures of Disease Severity.” Am J Ophthalmol. 2020; 219:87-100

勘误:“RUSH2A研究中的基线视场发现:相关因素与疾病严重程度其他指标的关联。” 美国眼科杂志。2020; 219:87-100

2025-08-050
PRE
REPLY

回复

2025-07-260
PRE
OCT-Defined Atrophic Age-Related Macular Degeneration Changes Associated with Deep Visual Sensitivity Losses: A Multicenter Study

OCT定义的萎缩性年龄相关性黄斑变性变化与深度视觉敏感度损失的关系:一项多中心研究

2025-07-160
OAAI
Designing the next generation of clinical trials in intermediate AMD-a consensus driven, pragmatic, proof of concept early intervention study

在中级AMD中设计下一代临床试验-共识驱动,务实,概念验证早期干预研究

2025-06-010
PRE
BASELINE VISUAL FIELD FINDINGS IN THE RUSH2A STUDY: ASSOCIATED FACTORS AND CORRELATION WITH OTHER MEASURES OF DISEASE SEVERITY (vol 219, pg 87, 2020)

RUSH2A研究中的基线视场发现:相关因素及与其他疾病严重程度指标的相关性(卷219,页87,2020)

2025-05-010
PRE
Effectiveness of Frequently Used TNF Inhibitors vs. Conventional Immunosuppressive Therapies for Noninfectious Uveitis

常用TNF抑制剂的疗效与常规免疫抑制疗法治疗非感染性葡萄膜炎的比较

2025-04-150
OA
Faricimab Treat-and-Extend for Diabetic Macular Edema
2024-06-0126
OA
Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study

通过视网膜下递送RGX-314对新生血管性年龄相关性黄斑变性进行基因治疗: 1/2a期剂量递增研究

LANCET
IF88.5
2024-04-0115
PRE